AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
IDEXX Laboratories to Participate in Morgan Stanley 23rd Annual Global Healthcare Conference.
ByAinvest
Tuesday, Sep 2, 2025 1:03 pm ET1min read
IDEXX Laboratories will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025. Jay Mazelsky, President and CEO, and Andrew Emerson, Executive Vice President and CFO, will engage in a fireside chat. A live audio webcast will be available on the IDEXX website. IDEXX is a global leader in pet healthcare innovation, providing diagnostic and software products and services to support veterinarians and advance medical care.
IDEXX Laboratories, Inc. (NASDAQ: IDXX), a leading innovator in pet healthcare, has announced that Jay Mazelsky, President and Chief Executive Officer, and Andrew Emerson, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025, from 1:50 pm to 2:25 pm (ET). The event will provide investors and industry stakeholders with the opportunity to engage with top executives from IDEXX Laboratories.The live audio webcast of the presentation will be available through a link on the IDEXX website, www.idexx.com/investors. An archived edition of the presentation will also be accessible via the same link. This event is part of IDEXX Laboratories' ongoing commitment to transparency and investor communication.
IDEXX Laboratories, headquartered in Maine, is a global leader in pet healthcare innovation. With a focus on diagnostic and software products and services, the company supports longer, fuller lives for pets by delivering insights and solutions to the veterinary community worldwide. IDEXX Laboratories employs approximately 11,000 people and offers solutions to customers in more than 175 countries and territories. The company is a member of the S&P 500® Index [1].
The fireside chat will offer insights into IDEXX Laboratories' strategic vision, financial performance, and innovations in pet healthcare. This event follows recent positive financial performance, with the company reporting a revenue growth rate of 10.55% over the three months ending June 30, 2025 [3]. Additionally, IDEXX Laboratories maintains a high gross margin of 62.62%, reflecting strong cost management and profitability [3].
Investors are encouraged to tune in to the live webcast or access the archived presentation for a comprehensive overview of IDEXX Laboratories' latest developments and future prospects.
References:
[1] https://www.marketscreener.com/news/idexx-laboratories-to-participate-in-morgan-stanley-23rd-annual-global-healthcare-conference-ce7d59dad98bf620
[2] https://www.streetinsider.com/Business+Wire/IDEXX+Laboratories+to+Participate+in+Morgan+Stanley+23rd+Annual+Global+Healthcare+Conference/25283775.html
[3] https://www.benzinga.com/insights/news/25/08/47361109/options-exercise-m-anne-szostak-at-idexx-laboratories-realizes-951k
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet